108 related articles for article (PubMed ID: 1348617)
1. Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets.
Ghigo D; Heller R; Calvino R; Alessio P; Fruttero R; Gasco A; Bosia A; Pescarmona G
Biochem Pharmacol; 1992 Mar; 43(6):1281-8. PubMed ID: 1348617
[TBL] [Abstract][Full Text] [Related]
2. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
3. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells.
Heller R; Bussolino F; Calvino R; Ghigo D; Alessio P; Todde R; Fruttero R; Pescarmona G; Gasco A; Till U
Agents Actions; 1993 Nov; 40(3-4):157-65. PubMed ID: 7517616
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase.
Brüne B; Ullrich V
Mol Pharmacol; 1987 Oct; 32(4):497-504. PubMed ID: 2890093
[TBL] [Abstract][Full Text] [Related]
5. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement.
Kobune K; Inoue M; Morikawa M; Tsuboi M; Takanami Y; Iwane Y; Kudo T
Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):153-65. PubMed ID: 1811279
[TBL] [Abstract][Full Text] [Related]
6. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
7. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets.
Yin K; Lai PS; Rodriguez A; Spur BW; Wong PY
Prostaglandins; 1995 Sep; 50(3):169-78. PubMed ID: 8750213
[TBL] [Abstract][Full Text] [Related]
11. Interaction of nitric oxide and cGMP with signal transduction in activated platelets.
Nguyen BL; Saitoh M; Ware JA
Am J Physiol; 1991 Oct; 261(4 Pt 2):H1043-52. PubMed ID: 1656783
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling.
Khamrang T; Hung KC; Hsia CH; Hsieh CY; Velusamy M; Jayakumar T; Sheu JR
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28448438
[TBL] [Abstract][Full Text] [Related]
16. High concentrations of exogenous arachidonate inhibit calcium mobilization in platelets by stimulation of adenylate cyclase.
Kowalska MA; Rao AK; Disa J
Biochem J; 1988 Jul; 253(1):255-62. PubMed ID: 2458717
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of 8-bromo cyclic GMP on an extracellular Ca2+-dependent arachidonic acid liberation in collagen-stimulated rabbit platelets.
Matsuoka I; Nakahata N; Nakanishi H
Biochem Pharmacol; 1989 Jun; 38(11):1841-7. PubMed ID: 2544181
[TBL] [Abstract][Full Text] [Related]
18. Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis.
Anwer K; Gabis J; Romstedt K; Gojer C; Huzoor-Akbar
Life Sci; 1985 Jul; 37(1):63-70. PubMed ID: 3925267
[TBL] [Abstract][Full Text] [Related]
19. 4-Methyl-3-(arylsulfonyl)furoxans: a new class of potent inhibitors of platelet aggregation.
Calvino R; Fruttero R; Ghigo D; Bosia A; Pescarmona GP; Gasco A
J Med Chem; 1992 Aug; 35(17):3296-300. PubMed ID: 1324320
[TBL] [Abstract][Full Text] [Related]
20. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ
Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
